

# Investigation Report on China's Palbociclib Market 2021-2025

<https://marketpublishers.com/r/I76E60E2F750EN.html>

Date: May 2021

Pages: 50

Price: US\$ 2,600.00 (Single User License)

ID: I76E60E2F750EN

## Abstracts

### Description

Palbociclib is the world's first selective inhibitor of CDK 4/6 launched by Pfizer. By inhibiting CDK 4/6, Palbociclib restores cell cycle control, thereby blocking tumor cell proliferation. Palbociclib is mainly used to treat advanced breast cancer. In 2018, Pfizer's Palbociclib, IBRANCE entered the Chinese market. By 2020, Pfizer Europe MA EEIG is the only manufacturer in the Chinese Palbociclib market.

According to CRI's market research, after Palbociclib went on the market in China, the sales increased rapidly from CNY298,630 in 2018 to CNY 22.01million in 2019. In 2020, the sales revenue was CNY13.18 million, which decreased 40.12% compared to that in 2019. The main reason is that the COVID-19 epidemic has impacted the overall hospitals' operation. The CAGR of Palbociclib from 2018 to 2020 is 564.36%.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Palbociclib will have a recovery growth from 2021 to 2025. Besides, the sales will also increase as the market expands. At the end of 2020, Pfizer applied for a new indication for Palbociclib in China. If the new indication is approved, the sales of Palbociclib will increase in the following years. On the other hand, Pfizer announced at the beginning of 2021 that it would reduce the price for Palbociclib by about 54%. Therefore, sales volume in 2021 is expected to increase, which will lead to revenue growth. At the same time, with the emergence of new CDK4/6 inhibitors and generic drugs in the Chinese market, the price of Palbociclib may continue to fall. The price reduction will make Palbociclib more affordable for patients, thus further opening up the market.

Topics Covered:

The impact of COVID-19 on China's Palbociclib market

Sales value of China's Palbociclib 2016-2020

Competitive landscape of China's Palbociclib market

Prices of Palbociclib in China

Prices of Palbociclib in China by regions and manufacturers

Analysis on factors affecting the development of China's Palbociclib market

Prospect of China's Palbociclib market from 2021 to 2025

## Contents

### **1 RELEVANT CONCEPTS OF PALBOCICLIB**

- 1.1 Indications for Palbociclib
- 1.2 Development of Palbociclib in China
- 1.3 Governmental Approval of Palbociclib in China
- 1.4 The Impact of COVID-19 on Palbociclib sales in China

### **2 SALES OF PALBOCICLIB IN CHINA, 2018-2020**

- 2.1 Sales Value of Palbociclib
  - 2.1.1 Overall Sales Value
  - 2.1.2 Sales Value by Region
- 2.2 Sales Volume of Palbociclib
  - 2.2.1 Overall Sales Volume
  - 2.2.2 Sales Volume by Regions
- 2.3 Sales of Palbociclib by Dosage Form in China, 2018-2020
  - 2.3.1 Capsule
  - 2.3.2 Analysis of Other Dosage Forms

### **3 ANALYSIS OF MAJOR PALBOCICLIB MANUFACTURERS IN CHINA, 2018-2020**

- 3.1 Analysis of Market Share of Major Palbociclib Manufacturers
  - 3.1.1 Investigation on Market Share by Sales Value
  - 3.1.2 Investigation on Market Share by Sales volume
- 3.2 Pfizer Europe MA EEIG
  - 3.2.1 Enterprise Profile
  - 3.2.2 Sales of IBRANCE (Pfizer's Palbociclib) in China

### **4 PRICES OF PALBOCICLIB FOR DIFFERENT MANUFACTURERS IN CHINA, 2020-2021**

- 4.1 Pfizer Europe MA EEIG (IBRANCE)

### **5 PROSPECT OF CHINESE PALBOCICLIB DRUG MARKET, 2021-2025**

- 5.1 Influential Factors of Chinese Palbociclib Market Development
  - 5.1.1 The Impact of COVID-19 on Chinese Palbociclib Market

- 5.1.2 Market Drivers and Opportunities
- 5.1.3 Market Threats and Challenges
- 5.2 Forecast on Market Size
- 5.3 Forecast on Market Trend

## List Of Charts

### LIST OF CHARTS

- Chart Patent Information About Palbociclib Capsule Registration in China
- Chart Sales Value of Palbociclib Capsule over the World
- Chart Sales Value of Palbociclib Capsule in China, 2018-2020
- Chart Sales Value of Palbociclib Capsule in China by Regions, 2018-2020
- Chart Sales Volume of Palbociclib Capsule in China, 2018-2020
- Chart Sales Volume of Palbociclib Capsule in China by Regions, 2018-2020
- Chart Market Share by Sales Value of Top Palbociclib Manufacturers in China, 2018-2020
- Chart Sales Value and Volume of IBRANCE in China, 2018-2020
- Chart Referential Prices of IBRANCE in China, 2020-2021
- Chart Forecast on Sales Value of Palbociclib in China, 2021-2025
- Chart Forecast on Sales Volume of Palbociclib in China, 2021-2025

## I would like to order

Product name: Investigation Report on China's Palbociclib Market 2021-2025

Product link: <https://marketpublishers.com/r/I76E60E2F750EN.html>

Price: US\$ 2,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I76E60E2F750EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970